List view / Grid view
A recent whole genome sequencing study has revealed hidden insights into the causes of cancer. In an exclusive article, Dr Andrea Degasperi from the Early Cancer Institute at the University of Cambridge, UK spoke to Drug Target Review's Ria Kakkad about the study's implications and the future of whole genome sequencing.
In a pre-clinical study, researchers from the US set out to develop a treatment for sepsis. Here, Daniel Morales-Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, describe how they utilised haematopoietic stem and progenitor cell infusion to improve the survival of mice from sepsis.
The endocannabinoid system may play a role in the development of autism spectrum disorder and might be key to treating people with severe forms of the condition. In this commentary, Dr Karen Litwa, Assistant Professor at East Carolina University’s Brody School of Medicine, US explores how a bioelectronic assay is…
A broader view of cellular processes during the drug discovery and development stages enabled by microscopy could help scientists to design better therapies for patients. In this interview, Drug Target Review’s Victoria Rees asks Dr Peter O’Toole, Head of Imaging and Cytometry at the University of York, UK about his…
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Michael Grange, Tomography Group Leader from the Rosalind Franklin Institute (RFI), UK about the advantages of using cryo-electron tomography imaging.
Antibiotic resistance is one of the key health challenges of the future. In a new study, researchers have carried out a multi-step analysis to deliver insights into translocation of the hydrophobic and hydrophilic portions of the large lipopolysaccharide molecules through the outer membrane of Neisseria gonorrhoeae. This article summarises their…
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
A new photonic effect in semiconducting helical particles with nanoscale dimensions has been discovered by an international team of scientists from the University of Bath, UK and the University of Michigan, US. Here, Professors Nicholas Kotov and Ventsislav Valev discuss their study and the observed effect which has the potential…
Drug testing on advanced cell-based models such as organoids has gained in popularity, but significant technical hurdles remain that prevent further assay miniaturisation and higher assay throughput. Through the replacement of animal-derived basement membranes with wood-derived nanofibrillar cellulose hydrogel (NFC), Dr Tijmen Booij and Dr Christian Stirnimann from ETH Zurich,…
Dr Erik Vernet, Director of Antibody Technology at Novo Nordisk, discusses antibody discovery and development workflows, including the role of informatics processes, in this Q&A.
Viral vectors to deliver gene therapies are utilised by clinically approved therapies. However, this method is not the only option for advanced therapeutics. In this piece, Brent Warner, President, Gene Therapy at Poseida Therapeutics, discusses the balance between efficacy and safety in gene therapy, highlighting positive pre-clinical data for non-viral…
Expectations are growing worldwide for discoveries that will harness the potential of cell therapy, which has already brought breakthroughs in therapeutic areas where there is an unmet need, from oncology to ophthalmology and rare disease. In this article, Dr Terri Gaskell, Chief Technology Officer at Rinri Therapeutics, explores some of…
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
In this article, Dr Mary Spellman, Chief Medical Officer and Senior Vice President of R&D at Castle Creek Biosciences, discusses how a versatile dual platform of ex vivo and in vivo gene therapy technologies is being utilised for the development of novel gene therapies for a broad range of rare…
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
